Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyVax Immunotherapy for CNS Lymphoma
NCT00621036Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Oct 2007
- Primary completion
- Dec 2008
- Countries
- 1
01
Overview
Phase 2, open-label trial of MyVax in central nervous system lymphoma, sponsored by UT Southwestern Medical Center. Primary endpoint: Anti-idiotype and anti-keyhole limpet hemocyanin immune response rate in the CSF. Planned start Oct 2007; status: withdrawn.
02
Drugs
MyVax
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT00621036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621036.